Celgene

Immunotherapies, biosimilars to dominate next week of earnings
Immunotherapies, biosimilars to dominate next week of earnings
Biopharma Dive
AbbVie
AstraZeneca
Bristol-Myers Squibb
Celgene
Roche
Vertex Pharmaceuticals
Sanofi
earnings
Flag link:
Celgene's Ozanimod Reduces Relapses and Brain Volume Loss in MS Patients in Phase III Trials
Celgene's Ozanimod Reduces Relapses and Brain Volume Loss in MS Patients in Phase III Trials
CP Wire
Celgene
ozanimod
relapsing multiple sclerosis
MS
Flag link:
2 Beta Thalassemia Drugs Are Fast Approaching the Finish Line
2 Beta Thalassemia Drugs Are Fast Approaching the Finish Line
Motley Fool
Celgene
Bluebird Bio
beta thalassemia
LentiGlobin
luspatercept
Flag link:
Pfizer's Deal Potential Doesn't Stop at Bristol-Myers
Pfizer's Deal Potential Doesn't Stop at Bristol-Myers
Bloomberg
Pfizer
M&A
Bristol-Myers Squibb
Celgene
Eli Lilly
AstraZeneca
Flag link:
Celgene on biotech hunt with Agios, Jounce in crosshairs: FT
Celgene on biotech hunt with Agios, Jounce in crosshairs: FT
Fierce Biotech
Celgene
M&A
Agios Pharmaceuticals
Jounce Therapeutics
Flag link:
Celgene, AbbVie extracted higher prices in Q4 as other pharmas netted less: report
Celgene, AbbVie extracted higher prices in Q4 as other pharmas netted less: report
Fierce Pharma
Celgene
AbbVie
drug pricing
Flag link:
Celgene Parts with COO Scott Smith “Effective Immediately”
Celgene Parts with COO Scott Smith “Effective Immediately”
Xconomy
Celgene
Scott Smith
Flag link:
Celgene, bluebird revise deal to co-develop CAR-T therapy
Celgene, bluebird revise deal to co-develop CAR-T therapy
Biopharma Dive
Celgene
Bluebird Bio
drug development
CAR-T
bb2121
Multiple Myeloma
Flag link:
Arena Pharmaceuticals Takes Aim at Celgene
Arena Pharmaceuticals Takes Aim at Celgene
Motley Fool
Arena Pharmaceuticals
Celgene
etrasimod
ozanimod
ulcerative colitis
Flag link:
Prothena, Celgene ink neuro R&D pact potentially worth $2B+
Prothena, Celgene ink neuro R&D pact potentially worth $2B+
Fierce Biotech
Prothena
Celgene
R&D
TDP-43
anti-tau antibodies
Alzheimer's disease
Flag link:
Why Amgen Shouldn't Use Its War Chest For A Celgene Megamerger
Why Amgen Shouldn't Use Its War Chest For A Celgene Megamerger
Investors Business Daily
Amgen
Celgene
M&A
Alexion
AstraZeneca
Flag link:
2 Biotech Stocks Near All-Time Highs: Can They Keep Climbing?
2 Biotech Stocks Near All-Time Highs: Can They Keep Climbing?
Motley Fool
biotech
BeiGene
China
Celgene
AnaptysBio
ANB020
eczema
Flag link:
Vividion Lands $101M from Celgene to Develop Protein-Targeting Drugs
Vividion Lands $101M from Celgene to Develop Protein-Targeting Drugs
Xconomy
Vividion
Celgene
drug development
protein-targeted drugs
Flag link:
Top 5 viewed boards for week ending March 3, 2018
Top 5 viewed boards for week ending March 3, 2018
CP Wire
cafepharma
Daiichi Sankyo
Shire
Allergan
Amgen
Sanofi
sales meeting
layoffs
Esmya
Pfizer
Celgene
M&A
Flag link:
How Bad Is Celgene's FDA Foul-Up? Two Decades Of Biotech History Says It Can't Be Good
How Bad Is Celgene's FDA Foul-Up? Two Decades Of Biotech History Says It Can't Be Good
Forbes
Celgene
biotech
FDA
RTF letters
ozanimod
Flag link:
Celgene stumbles again, as FDA declines to review multiple sclerosis drug critical to company future
Celgene stumbles again, as FDA declines to review multiple sclerosis drug critical to company future
Stat
Celgene
FDA
MS
multiple sclerosis
ozanimod
Flag link:
Bristol losing its I/O talent to the likes of Pfizer, report finds
Bristol losing its I/O talent to the likes of Pfizer, report finds
Biopharma Dive
Bristol-Myers Squibb
Pfizer
Celgene
immuno-oncology
R&D
Flag link:
3 Big Drugmakers Boosting Huge R&D Budgets
3 Big Drugmakers Boosting Huge R&D Budgets
Motley Fool
R&D
Bristol-Myers Squibb
Celgene
JNJ
Flag link:
How Celgene Hopes to Cash In on CAR-T
How Celgene Hopes to Cash In on CAR-T
Yahoo/Motley Fool
Celgene
CAR-T
JCAR017
bb2121
Bluebird Bio
Flag link:
Celgene Spinout Celularity Raises $250 Million To Develop Placental Cells To Attack Cancer
Celgene Spinout Celularity Raises $250 Million To Develop Placental Cells To Attack Cancer
Forbes
Celgene
Celularity
placental-based cells
tumors
cancers
biotech
Flag link:

Pages